
Validea's guru fundamental report indicates that Johnson & Johnson (JNJ) receives an 87% rating based on their Multi-Factor Investor model, which is based on the strategy of Pim van Vliet and favors low volatility stocks with strong momentum and high net payout yields; while JNJ passed the market cap and standard deviation tests, it was neutral on momentum and net payout yield, ultimately failing the final rank within this specific strategy.
Johnson & Johnson (JNJ) has been highlighted by Validea's guru fundamental report, achieving an 87% rating under its Multi-Factor Investor model, which is based on Pim van Vliet's strategy favoring low volatility, strong momentum, and high net payout yields. This score, which typically signals a degree of interest as it surpasses the 80% threshold, reflects JNJ's status as a large-cap growth stock in the Biotechnology & Drugs industry. The company successfully met the model's criteria for market capitalization and standard deviation, aligning with the strategy's emphasis on low-volatility characteristics. However, JNJ received neutral ratings for both "twelve minus one momentum" and "net payout yield." Crucially, despite the strong initial score and positive volatility metrics, the detailed assessment concluded with a "FAIL" for JNJ on the strategy's "FINAL RANK," indicating that it does not fully satisfy all the explicit conditions required for a definitive endorsement by this particular quantitative investment model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment